<DOC>
	<DOCNO>NCT02487160</DOCNO>
	<brief_summary>The purpose study evaluate safety performance SBL-3 intraocular lens .</brief_summary>
	<brief_title>Clinical Evaluation Lenstec SBL-3 Multifocal Intraocular Lens</brief_title>
	<detailed_description>The purpose study evaluate safety ( adverse event ) performance ( visual acuity , spectacle independence ) SBL-3 intraocular lens .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Presbyopia</mesh_term>
	<criteria>1 . ≥ 22 year age , race either gender 2 . Operable , age relate cataract grade eye 3 . Patients require intraocular lens ( IOL ) power range 15 D 30 D 4 . Able comprehend sign statement inform consent 5 . Calculated lens power within available supply range 6 . Planned cataract removal phacoemulsification 7 . Potential postoperative visual acuity 0.2 Logarithm Minimum Angle Resolution ( logMAR ) good eye 8 . In good general ocular health 9 . Patients preoperative astigmatism ≤1.0 D Note : Corneal incision make reduce astigmatism allow course study . 10 . Clear intraocular medium cataract study eye 11 . Preoperative Best Corrected Distance Visual Acuity ( BCDVA ) worse 0.2 logMAR 12 . The subject must able undergo second eye surgery 7 day 30 day first eye surgery 13 . Able competently complete test 14 . Willing able attend study visit 1 . Previous intraocular surgery 2 . Preoperative photopic pupil size &lt; 2.75 mm 3 . Previous corneal refractive surgery 4 . Any inflammation edema ( swell ) cornea 5 . Subjects diagnose degenerative visual disorder ( e.g . macular degeneration retinal disorder ) predict cause future acuity loss level bad 0.2 logMAR 6 . Subjects may reasonably expect require secondary surgical intervention time study ( neodymiumdoped yttrium aluminium garnet ( nd : YAG ) capsulotomy ) 7 . Amblyopia 8 . Clinically significant ptosis 9 . Clinically severe corneal dystrophy ( eg. , epithelial , stromal , endothelial dystrophy ) , keratitis , keratoconjunctivitis , keratouveitis , keratopathy , kerectasia 10 . Diabetic Retinopathy 11 . Extremely shallow anterior chamber , due swell cataract 12 . Microphthalmia 13 . Previous retinal detachment 14 . Previous corneal transplant 15 . Severe dry eye 16 . Recurrent severe anterior posterior segment inflammation unknown etiology 17 . Systemic medication may confound outcome increase risk subject opinion Investigator [ tamsulosin hydrochloride ( Flomax ) medication similar side effect ( floppy iris syndrome ) ] 18 . Rubella traumatic cataract 19 . Iris neovascularization 20 . Glaucoma ( medically control uncontrolled ) 21 . Aniridia 22 . Chronic severe uveitis 23 . Optic nerve atrophy 24 . Corneal decompensation 25 . Greater 1.0 D astigmatism 26 . History corneal disease ( e.g. , herpes simplex , herpes zoster keratitis , etc . ) 27 . Pseudoexfoliation syndrome 28 . Iris atrophy 29 . Pupil abnormality ( e.g. , corectopia ) 30 . Aniseikonia 31 . An acute chronic disease illness may confound result investigation ( e.g. , immunocompromised , connective tissue disease , clinically significant atopic disease , diabetes , disease illness ) 32 . Pregnant , lactating , plan become pregnant course trial Note : Subjects become pregnant study discontinue ; however , data may exclude effectiveness analysis pregnancy alter refraction visual acuity result . 33 . Participation another clinical trial within 30 day study start</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>